๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A monoclonal antibody specific for membrane associated differentiation marker of human stratified squamous epithelia and squamous cell carcinoma

โœ Scribed by Harada, H.; Tashiro, H.; Kurisu, K.; Yasumoto, S.


Book ID
122866123
Publisher
Elsevier Science
Year
1991
Tongue
English
Weight
105 KB
Volume
2
Category
Article
ISSN
0923-1811

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


A monoclonal antibody KIS-1 recognizing
โœ Uhi Toh; Hideaki Yamana; Hiromasa Fujita; Yuji Toh; Teruhiko Fujii; Keisuke Kubo ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 867 KB

A KIS-I monoclonal antibody (MAb) &GI, K) recognizing a membrane antigen on human squamous-cell carcinomas (SCC) was developed to understand their antigenicity using an esophageal SCC as an immunogen. The KIS-I MAb recognized a membrane antigen on a majority of esophageal, lung, and oralcavity SCC b

UNME/K1: an IgG2a monoclonal antibody sp
โœ El-Mohamady, H. ;Basta, M. T. ;Seddek, M. N. ;Helmy, H. ;Al-Hilaly, E. ;Attallah ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› Springer ๐ŸŒ English โš– 724 KB

The main distinctive feature of carcinoma in schistosomal bladder is keratinized squamous cell carcinoma. Keratins/cytokeratins constitute a multigeneic family of structurally related polypeptide markers for the malignant state of epithelial cells. A monoclonal antibody (UNME/K1) regognizing keratin

Murine monoclonal antibody LAM2 defines
โœ Rolf A. Stahel; Jonathan A. Speak; Samuel D. Bernal ๐Ÿ“‚ Article ๐Ÿ“… 1985 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 720 KB

## Abstract Murine monoclonal antibodies (MAbs) were generated against a human undifferentiated lung carcinoma cell line. The hybridoma designated LAM2 produced an IgM kappa MAb with reactivity to the cell membrane. Indirect immunofluorescence staining and radioimmunoassays showed LAM2 antibody to

Monoclonal antibody U36, a suitable cand
โœ Nicole L.W. Van Hal; Guus A.M.S. Van Dongen; Ellen M.C. Rood-Knippels; Paul Van ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 827 KB

At present, tumor-targeting with monoclonal antibodies ( M U ) is among the most promising novel adjuvant-therapy modalities for the treatment of patients with minimal residual disease of head-and-neck squamous-cell carcinoma (HNSCC For this purpose we developed MAb U36, recognizing a 2 d kDa antige